Company Valuation: Thiogenesis Therapeutics, Corp.

Data adjusted to current consolidation scope
Fiscal Period: December 2022 2023 2024 2025
Market Cap 1 22.54 33.43 27.61 33.69
Change - 48.3% -17.4% 22.03%
Enterprise Value (EV) 1 16.34 26.35 23.76 32.08
Change - 61.23% -9.83% 34.99%
P/E -3.74x -5.8x -8.65x -4.25x
PBR 3.77x 6.04x 8.06x 58.7x
PEG -0x 0.3x 0.2x -0x
Capitalization / Revenue - - - -
EV / Revenue - - - -
EV / EBITDA - - - -
EV / EBIT -8.14x -5.06x -6.64x -4.34x
EV / FCF - - - -
FCF Yield - - - -
Dividend per Share 3 - - - -
Rate of return - - - -
EPS 3 -0.1552 -0.1294 -0.0693 -0.1528
Distribution rate - - - -
Net sales - - - -
EBITDA - - - -
EBIT 1 -2.009 -5.206 -3.579 -7.395
Net income 1 -3.924 -5.063 -3.146 -7.426
Net Debt 1 -6.196 -7.076 -3.848 -1.616
Reference price 3 0.5800 0.7500 0.6000 0.6500
Nbr of stocks (in thousands) 38,862 44,571 46,017 51,836
Announcement Date 28/04/23 29/04/24 25/04/25 30/04/26
1CAD in Million2USD in Million3CAD
Estimates

P/E (Y) EV / Sales (Y) EV / EBITDA (Y) Dividend Yield (Y) Capi.($)
34.4x6.13x18.24x0.93% 51.22B
-21.71x301.09x-22.35x-.--% 45.38B
48.36x5.61x30.68x-.--% 41.97B
32.97x3.21x13.87x-.--% 42.15B
29.48x8.52x21.54x0.39% 31.95B
34.84x5.71x25.97x-.--% 17.1B
24.28x2.11x9.12x1.11% 14.76B
77.97x4.1x15.89x-.--% 13.91B
Average 32.57x 42.06x 14.12x 0.3% 32.31B
Weighted average by Cap. 27.77x 57.29x 12.69x 0.3%

Y-o-Y evolution of P/E

Historical PBR trend

Evolution Enterprise Value / Sales

Change in Enterprise Value/EBITDA

  1. Stock Market
  2. Stocks
  3. TTI Stock
  4. TTIPF Stock
  5. Valuation Thiogenesis Therapeutics, Corp.